Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Joins FCA Case Against Alere Unit

Executive Summary

Alere subsidiary Arriva Medical routinely gave Medicare beneficiaries glucometers they didn’t need and billed the government for them, a recently unsealed lawsuit claims.

You may also be interested in...



DOJ: Alere Unit Billed Medicare For Diabetic Testing Supplies For The Dead

Alere Medical and its now-defunct subsidiary Arriva Medical will pay the US government $160m to settle allegations that they violated the False Claims Act. It’s the second settlement that Alere has entered into with the Department of Justice in recent weeks.

Despite Legal Dispute, Abbott Set To Buy Alere for $5.3bn

Soon before it was set to take Alere to court in an attempt to break out of an acquisition deal, Abbott has reversed course and plans to buy the company for half a billion less than the original price tag.

Alere Challenges Medicare Billing Block

The company, which had its Medicare supplier billing number revoked in November, filed an appeal with an administrative law judge. Alere also asked the US District Court for the District of Columbia to force CMS to allow its Arriva unit to stay in the competitive bidding program while the ALJ appeal is pending.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel